Tyler Van Buren, an analyst from TD Cowen, maintained the Hold rating on Moderna (MRNA – Research Report). The associated price target remains the same with $35.00.
Tyler Van Buren’s rating is based on several factors that are influencing Moderna’s current and future financial performance. The company is at a crucial turning point, facing challenges such as declining vaccination rates and increased competition, which are expected to result in flat year-over-year sales by 2025. The company’s objective of breaking even by 2028 is heavily reliant on the successful development and commercialization of new respiratory and latent virus vaccines, which must be executed flawlessly amid decreasing operational expenses.
Furthermore, Moderna’s Q4 sales of its COVID-19 vaccine, Spikevax, showed a significant decline from the previous year. This decline is attributed to a drop in COVID booster vaccination rates and a loss of market share to competitors, although there is still substantial utilization among elderly and at-risk groups. The company’s revenue guidance for 2025 has been adjusted downward, reflecting the anticipated decrease in demand and competition. To achieve its financial goals, Moderna must successfully launch three major products, manage costs, optimize manufacturing, and navigate regulatory challenges.
In another report released on January 30, Bernstein also maintained a Hold rating on the stock with a $45.00 price target.